REGN vs VRTX
REGN: Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | REGN | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $667.95 | $498.43 | |
| Market cap as of 2026-07-10 | $69.9B | $130.3B | |
| P/E as of 2026-07-10 | 15.80 | 30.05 | REGN lower |
| PEG as of 2026-07-10 | 1.01 | 2.31 | REGN lower |
| Net margin as of 2026-07-10 | +29.6% | +35.5% | VRTX higher |
| Gross margin as of 2026-07-10 | +85.7% | +86.2% | VRTX higher |
| Operating margin as of 2026-07-10 | +24.3% | +38.3% | VRTX higher |
| ROE as of 2026-07-10 | +14.3% | +23.9% | VRTX higher |
| ROA as of 2026-07-10 | +11.1% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-10 | 0.09 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-07-10 | +5.9% | +10.1% | VRTX higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | +10.4% | VRTX higher |
| Dividend yield as of 2026-07-10 | +0.6% | n/a | |
| Beta as of 2026-07-10 | 0.21 | 0.29 | |
| 1-year return as of 2026-07-09 close | +20.9% | +6.9% | REGN higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.